US FDA panel backs JAK; thumbs up for Pfizer's tofacitinib in RA
This article was originally published in Scrip
Executive Summary
Although a majority of outside advisers to the US FDA said they would like to see more data on Pfizer's tofacitinib, the agency's Arthritis Advisory Committee on 9 May backed approval of the drug – potentially opening the gateway for the second Janus kinase (JAK) inhibitor to soon enter the US market, and the first in the rheumatoid arthritis (RA) space.